Attain FDA Label Claims for Kinase Inhibitor Drugs with the Simcyp™ Simulator Fact Sheet Attain FDA Label Claims for Kinase Inhibitor Drugs with the Simcyp™ Simulator Simcyp was used by pharma and biotech companies to inform, reduce and/or replace clinical studies…Certara2023 年 12 月 6 日
American College of Toxicology 2025 Annual Meeting Conference American College of Toxicology 2025 Annual Meeting – – BoothCertara2023 年 5 月 24 日
Using PBPK Models to Predict Effects of Hepatic Impairment & DDI in Olanzapine/Samidorphan Combination Therapy Case Study Using PBPK Models to Predict Effects of Hepatic Impairment & DDI in Olanzapine/Samidorphan Combination Therapy Olanzapine is an effective antipsychotic medication used to treat schizophrenia, a disease that affects about…Certara2022 年 10 月 31 日
Why you should select your drug formulation before starting clinical studies Blog 为何应在开始临床研究前选择药物制剂 药物开发者常急于推进发现流程以进入人体试验。Most are…Certara2022 年 10 月 28 日
Simcyp Discovery Simulator Brochure Simcyp™ Discovery Simulator Tailored for discovery and translational scientists, Simcyp Discovery Simulator is an intuitive software that delivers…Certara2022 年 7 月 14 日
Simcyp Simulator Helps Optimize Drug Dosing in Adults & Adolescents with Orphan Disease Case Study Simcyp Simulator 有助于优化成人和青少年孤儿病患者的用药剂量 全世界约有 400,000 名先天性肾上腺增生症(CAH)患者。Current therapy for CAH uses a…Certara2022 年 6 月 6 日
PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA Case Study PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA In 2020, the US FDA approved Risdiplam (Evrysdi®) as the first orally administered drug to…Certara2022 年 6 月 2 日
PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Case Study PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to…Certara2022 年 4 月 11 日